Invariant Natural Killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Tincati, Camilla ^a   Basilissi, Matteo ^a   Sinigaglia, Elisabetta ^b   Merlini, Esther ^a   Carpani, Giovanni ^b   Monforte, Antonella D'Arminio ^a   Marchetti, Giulia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD161 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR; TUMOR NECROSIS FACTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY B;

ADULT; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVARIANT NATURAL KILLER T CELL; LYMPHOCYTE FUNCTION; MALE; NATURAL KILLER T CELL; OSTEOPOROSIS; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; CASE CONTROL STUDY; COMPLICATION; GENETICS; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B;

EID: 84908125424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110287     Document Type: Article

References (59)

1. Deeks SG, Lewin SR, Havlir DV (2013) The end of AIDS: HIV infection as a chronic disease. Lancet 382: 1525-1533.
2. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, et al. (2010) High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 201: 285-292.
3. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, et al. (2010) Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115: 161-167.
4. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788-1795.
5. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, et al. (1993) Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 6: 904-912.
6. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, et al. (1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16: 83-92.
7. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-870.
8. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-1543.
9. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, et al. (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128: 92-105.
10. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
11. Desai S, Landay A (2010) Early immune senescence in HIV disease. Curr HIV/AIDS Rep 7: 4-10.
12. Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, et al. (2009) Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 50: 299-306.
13. Gazzola L, Bellistri G, Tincati C, Ierardi V, Savoldi A, et al. (2013) Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med 11: 1-10.
14. Tincati C, Bellistrì GM, Casana M, Merlini E, Comi L, et al. (2009) CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease. J Acquir Immune Defic Syndr 51: 642-644.
15. Merlini E, Luzi K, Suardi E, Barassi A, Cerrone M, et al. (2012) T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 7: e46073.
16. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, et al. (2011) T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 203: 452-463.
17. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, et al. (2011) T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 217: 207-213.
18. Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N, et al. (2013) Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 14: 385-390.
19. Bendelac A (1995) CD1: presenting unusual antigens to unusual T lymphocytes. Science 269: 185-186.
20. Bendelac A, Rivera MN, Park SH, Roark JH (1997) Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15: 535-562.
21. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629.
22. de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, et al. (2004) Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 173: 1417-1425.
23. Joyee AG, Qiu H, Wang S, Fan Y, Bilenki L, et al. (2007) Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J Immunol 178: 1048-1058.
24. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, et al. (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4RSTAT6 pathway. Nat Immunol 1: 515-520.
25. Snyder-Cappione JE, Nixon DF, Chi JC, Nguyen ML, Kirby CK, et al. (2013) Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis. Eur J Immunol 43: 2194-2205.
26. Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH (2011) The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 3: 1167-1184.
27. Juno JA, Keynan Y, Fowke KR (2012) Invariant NKT cells: regulation and function during viral infection. PLoS Pathog 8: e1002838.
28. Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, et al. (2012) Activated iNKT cells promote memory CD8 + T cell differentiation during viral infection. PLoS One 7: e37991.
29. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, et al. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191: 661-668.
30. Snyder-Cappione JE, Nixon DF, Loo CP, Chapman JM, Meiklejohn DA, et al. (2007) Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J Infect Dis 195: 1361-1364.
31. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, et al. (2002) Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol 76: 7528-7534.
32. Snyder-Cappione JE, Loo CP, Carvalho KI, Kuylenstierna C, Deeks SG, et al. (2009) Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS 23: 1965-1970.
33. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, et al. (2002) CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 195: 869-879.
34. van der Vliet HJ, von Blomberg BM, Hazenberg MD, Nishi N, Otto SA, et al. (2002) Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol 168: 1490-1495.
35. Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, et al. (2009) Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 39: 902-911.
36. Fleuridor R, Wilson B, Hou R, Landay A, Kessler H, et al. (2003) CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection. Immunology 108: 3-9.
37. Ibarrondo FJ, Wilson SB, Hultin LE, Shih R, Hausner MA, et al. (2013) Preferential depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection. Mucosal Immunol 6: 591-600.
38. Vasan S, Poles MA, Horowitz A, Siladji EE, Markowitz M, et al. (2007) Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol 19: 943-951.
39. van der Vliet HJ, van Vonderen MG, Molling JW, Bontkes HJ, Reijm M, et al. (2006) Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol 177: 5775-5778.
40. Yang OO, Wilson SB, Hultin LE, Detels R, Hultin PM, et al. (2007) Delayed reconstitution of CD4+ iNKT cells after effective HIV type 1 therapy. AIDS Res Hum Retroviruses 23: 913-922.
41. Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, et al. (2004) Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 24: 2351-2357.
42. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, et al. (2004) CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 199: 417-422.
43. To K, Agrotis A, Besra G, Bobik A, Toh BH (2009) NKT cell subsets mediate differential proatherogenic effects in ApoE-/- mice. Arterioscler Thromb Vasc Biol 29: 671-677.
44. Ostos MA, Recalde D, Zakin MM, Scott-Algara D (2002) Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 519: 23-29.
45. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, et al. (2004) Natural killer T cells accelerate atherogenesis in mice. Blood 104: 2051-2059.
46. VanderLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, et al. (2007) Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol 170: 1100-1107.
47. Aslanian AM, Chapman HA, Charo IF (2005) Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 25: 628-632.
48. Melián A, Geng YJ, Sukhova GK, Libby P, Porcelli SA (1999) CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol 155: 775-786.
49. Kyriakakis E, Cavallari M, Andert J, Philippova M, Koella C, et al. (2010) Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur J Immunol 40: 3268-3279.
50. Andoh Y, Fujii S, Iwabuchi K, Yokota T, Inoue N, et al. (2006) Lower prevalence of circulating natural killer T cells in patients with angina: a potential novel marker for coronary artery disease. Coron Artery Dis 17: 523-528.
51. Chan WL, Pejnovic N, Hamilton H, Liew TV, Popadic D, et al. (2005) Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ Res 96: 675-683.
52. Hu M, Bassett JH, Danks L, Howell PG, Xu K, et al. (2011) Activated invariant NKT cells regulate osteoclast development and function. J Immunol 186: 2910-2917.
53. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929-1936.
54. Salonen JT, Salonen R (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87: II56-65.
55. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, et al. (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146: 483-494.
56. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI (2005) Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol 35: 1399-1407.
57. Sandberg JK, Stoddart CA, Brilot F, Jordan KA, Nixon DF (2004) Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad Sci U S A 101: 7058-7063.
58. Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, et al. (2000) Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121: 77-88.
59. Fernandez CS, Kelleher AD, Finlayson R, Godfrey DI, Kent SJ (2014) NKT cell depletion in humans during early HIV infection. Immunol Cell Biol 92: 578-590.